NewsBenzingaB of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130 B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130 Benzinga 2026.09.28 17:23 (GMT+0) Open on Benzinga Other news Tesla Begins FSD v15 Rollout to First-Wave Customers A $150 Billion Reason to Buy the Nvidia Stock Dip Eli Lilly’s Next Weight-Loss Drug Helped Patients Lose Up to 54 Pounds. Why the FDA’s New Warning Didn’t Hurt LLY Stock. Galaxy Digital shares fall 8% Friday, weekly decline exceeds 20% Lean Groups Certify Claude-Assisted Riemann Proof Here are the top AI agents that can live in your text messages
Eli Lilly’s Next Weight-Loss Drug Helped Patients Lose Up to 54 Pounds. Why the FDA’s New Warning Didn’t Hurt LLY Stock.